Why the study?
Doxorubicin efficacy is limited by severe adverse effects including irreversible cardiotoxicity, motivating research into mechanisms to overcome toxicity without sacrificing efficacy.
Design
Review
Authors
Loading...
May inform design of anthracycline analogues with reduced cardiotoxicity; leaves open clinical translation pending prospective validation.
Separating the DNA-damaging and chromatin-damaging activities of doxorubicin could lead to new anthracycline analogues with preserved efficacy and reduced cardiotoxicity.
Zanden et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: